Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin

Chinese Medical Journal

Volumn 125, Issue 10, 2012, Pages 1690-1694

  Lu, Ying Li ^a,b   Zhou, De Quan ^b   Zhai, Hua Ling ^a   Hui, Wu ^a   Guo, Zeng Kui ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MAYO CLINIC   (United States)

Author keywords

Glycerol; Hepatic glucose production; Lipolysis; Obesity; Sitagliptin

Indexed keywords

CARBON 14; FATTY ACID; GLUCOSE; GLYCEROL; INSULIN; SITAGLIPTIN; TRIACYLGLYCEROL LIPASE; TRITIUM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ASSAY; ESTERIFICATION; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE METABOLISM; LIPOLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RAT; ANIMAL; DRUG EFFECT; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSE; LIVER; MALE; OBESITY; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 84871685830     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.10.003     Document Type: Article

References (24)

1. Schlaich MP, Grassi G, Lambert GW, Straznicky N, Esler MD, Dixon J, et al. European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. J Hypertens 2009; 27: 207-211.
2. Ross NA, Gilmour H, Dasgupta K. 14-year diabetes incidence: the role of socio-economic status. Health Rep 2010; 21: 19-28.
3. Bock G, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Chandramouli V, et al. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes 2007; 56: 1703-1711
4. McCormack JG, Westergaard N, Kristiansen M, Brand CL, Lau J. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Des 2001; 7: 1451-1474.
5. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. Clin Invest 2004; 113: 1582-1588.
6. Shah P, Basu A, Rizza R. Fat-induced liver insulin resistance. Curr Diab Rep 2003; 3: 214-218.
7. Bock G, Dalla Man C, Mcheletto F, Basu R, Giesler PD, Laugen J, et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010; 73: 189-196.
8. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009; 83: 106-116.
9. Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008; 10: 1212-1220.
10. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mckel C, Williams-Herman DE; Sitagliptin Study 021 Group. Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
11. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
12. Guo Z, Zhou L. Dual tail catheters for infusion and sampling in rats as an efficient platform for metabolic experiments. Lab Animal 2003; 32: 45-48.
13. Guo ZK, Jensen MD. Accelerated intramyocellular triglyceride synthesis in skeletal muscle of high-fat-induced obese rats. Int J Obesity 2003; 27: 1014-1019.
14. Folch J, Lees M, Sloane-Standley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
15. Dole VP. A relation between non-esterfied fatty acids in plasma and the metabolism of glucose. J Clin Invest 1956; 35: 150-154.
16. Guo ZK, Jensen MD. Blood glycerol is an important precursor for intramuscular triacylglycerol synthesis. J Biol Chem 1999; 274: 23702-23706.
17. Radziuk J, Pye S. Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution. Diabetologia 2002; 45: 1053-1084.
18. Jenssen T, Nurjhan N, Consoli A, Gerich JE. Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. Demonstration of hepatic autoregulation without a change in plasma glucose concentration. J Clin Invest 1990; 86: 489-497.
19. Gastaldelli A, Myazaki Y, Pettiti M, Buzzigoli E, Mahankali S, Ferrannini E, et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 2004; 89: 3914-3921.
20. Trimmer JK, Casazza GA, Horning MA, Brooks GA. Autoregulation of glucose production in men with a glycerol load during rest and exercise. Am J Physiol Endocrinol Metab 2001; 280: E657-E668.
21. Shah P, Basu A, Rizza R. Fat-induced liver insulin resistance. Curr Diab Rep 2003; 3: 214-218.
22. Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 459-464.
23. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-2952.
24. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002; 4: 145-151.